Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.4%) at 16,500 as of Friday, April 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,273 issues advancing vs. 1,704 declining with 143 unchanged. The Drugs industry currently sits down 3.6% versus the S&P 500, which is down 0.5%. Top gainers within the industry include Mylan ( MYL), up 4.1%, and Merck ( MRK), up 0.6%. On the negative front, top decliners within the industry include Illumina ( ILMN), down 6.2%, Alexion Pharmaceuticals ( ALXN), down 5.4%, Valeant Pharmaceuticals International ( VRX), down 4.4%, Regeneron Pharmaceuticals ( REGN), down 2.7% and Gilead ( GILD), down 2.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.51 (1.3%) to $39.16 on average volume. Thus far, 3.9 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 8.5 million shares. The stock has ranged in price between $38.83-$39.50 after having opened the day at $38.87 as compared to the previous trading day's close of $38.65. Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $59.5 billion and is part of the health care sector. Shares are up 0.8% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Abbott Laboratories Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.